Published Paper Details:

Mucormycosis is an uncommon but life-threatening infection with nonspecific infection clinical manifestation that makes its diagnosis treatment difficult. Genera from the order Mucorales (Rhizopus, Mucor, Rhizomucor, Absidia, Apophysomyces) cause an Angio invasive infection called an Mucormycosis. Mucormycosis presents with rhino-orbito-cerebral, pulmonary, disseminated, cutaneous, or gastrointestinal involvement. Mucormycosis has few available treatments including Liposomal Amphotericin B, Amphotericin B Deoxycholate, Itraconazole, Posaconazole or their combination, echinocandin, Voriconazole, and herbal extracts such as Tetradine, Rhizophora mangle, Picrohiza kurrhoa, they are most widely used as antifungal agent. Mucormycosis was difficult to study on imaging study surgery plus antifungal therapy close yields greater survival rate. LAmB is formulation that results in reduce nephrotoxicity as compared with DAmB (Deoxycholate Amphotericin B) while retaining the antifungal effect of active agent. Clinical approach to diagnosis lacks sensitivity and speficity. Development of quantitative Polymerase Chain Reaction (PCR) is promising area of ongoing research to enable more rapid diagnosis. The molecular pharmacology, preclinical, and clinical pharmacokinetics and clinical experience with LAmB for the most commonly encountered fungal pathogens are reviewed.